Taken together, our results have clearly shown the LDLR pathway to represent a metabolic vulnerability in both paediatric and adult high-grade gliomas, which potentially circumvents intra- and inter-tumour heterogeneity and is therefore potentially amenable to future lipoprotein based anti-LDLR nanotherapy, ubiquitously in patient cohorts. The gene discussed is LDLR; the disease is neoplasm.